Guardant Health
GH
$114.97
+17.09%
Guardant Health is a leader in the liquid biopsy diagnostics industry, specializing in non-invasive blood tests for cancer detection, genomic profiling, and monitoring. The company operates as a disruptive force in the medical diagnostics and research sector, leveraging its proprietary technology to offer tests like Guardant360 for tumor profiling, Shield for colorectal cancer screening, and Reveal for molecular residual disease. The current investor narrative is intensely focused on the company's path to profitability amidst rapid revenue growth, the scaling of its screening business, and its positioning within the broader trend of precision oncology, with recent financial trends showing significant year-over-year revenue expansion but ongoing substantial losses.…
GH
Guardant Health
$114.97
Related headlines
Investment Opinion: Should I buy GH Today?
Rating: Hold. The core thesis is that while Guardant Health is a compelling long-term growth story in a transformative market, its current valuation fully reflects this potential and introduces asymmetric risk if execution stumbles.
Supporting evidence includes the company's strong 39.4% YoY revenue growth and improving net margin trajectory (-45.7% in Q4 vs. -68.2% in Q1 2024). However, it trades at a lofty Price-to-Sales multiple of 13.0 and an EV/Sales of 12.7, which are high even for a growth stock. The stock is also 50% more volatile than the market (beta 1.49), increasing risk. While analyst sentiment is overwhelmingly bullish (10 Buy ratings out of 13), the lack of a specific consensus price target makes the implied upside difficult to quantify, leaving valuation as the primary concern.
The two biggest risks that could invalidate a Hold thesis are 1) a deceleration in quarterly revenue growth below 30%, and 2) a widening of net losses, signaling a failure to achieve operating leverage. This Hold would upgrade to a Buy if the PS ratio compressed meaningfully (e.g., below 9-10x) on sustained growth, or if the company provided a clear, near-term path to positive free cash flow. It would downgrade to Sell if revenue growth decelerated sharply or cash burn accelerated. The stock is currently overvalued relative to its financial profile, pricing in perfection.
Sign up to view all
GH 12-Month Price Forecast
Guardant Health is a high-quality growth story caught at a high-price crossroads. The fundamental trajectory is positive, with accelerating revenue and improving margins, yet the stock's valuation leaves no margin for error. The neutral stance reflects the belief that the current price fairly balances these exceptional growth prospects against the substantial execution and valuation risks. The stance would upgrade to Bullish on evidence of sustained >35% growth coupled with a meaningful de-risking of the path to profitability (e.g., guided timeline to FCF breakeven). It would downgrade to Bearish on any material growth deceleration or expansion of losses.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Guardant Health's 12-month outlook, with a consensus price target around $149.46 and implied upside of +30.0% versus the current price.
Average Target
$149.46
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$92 - $149
Analyst target range
The stock benefits from substantial analyst coverage, with 13 firms providing estimates, and the institutional sentiment is overwhelmingly bullish, as evidenced by ten recent ratings all reiterating Buy, Overweight, or Outperform equivalents, with only one firm maintaining an 'In Line' rating. While a consensus price target is not explicitly provided, the strong buy-side bias and the average revenue estimate of $3.15 billion for the forward period suggest analysts are projecting continued robust growth. The wide dispersion in forward EPS estimates, ranging from $2.44 to $2.75, indicates some uncertainty around the precise pace of bottom-line improvement, though the overall direction is positive. This high level of institutional analyst interest and generally favorable sentiment is typical for a high-profile growth story like Guardant Health, though the lack of a specific price target range in the data limits the precision of implied upside calculations.
Bulls vs Bears: GH Investment Factors
The bull case for Guardant Health is compelling, anchored by its 39.4% YoY revenue growth, improving operating leverage, and strong analyst support. However, the bear case presents formidable counterpoints, primarily the company's deep losses (-45.7% net margin) and the extreme valuation (PS of 13.0) that demands flawless execution. Currently, the bull side has stronger evidence due to the accelerating top-line growth and clear margin improvement trend. The single most important tension in the investment debate is the race between revenue scaling and cash burn: whether the company can achieve profitability before its cash runway or investor patience runs out, justifying its premium sales multiple.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 39.4% year-over-year to $281.3 million, accelerating from $203.5 million in Q1 2025. This demonstrates strong market adoption and execution across its core Oncology and emerging Screening segments.
- Improving Operating Leverage: The net margin improved from -68.2% in Q1 2024 to -45.7% in Q4 2025, a significant relative improvement of 22.5 percentage points. This trend indicates that losses are narrowing as revenue scales, a critical step toward eventual profitability.
- Overwhelming Analyst Bullishness: Institutional sentiment is strongly positive, with 10 out of 13 recent analyst ratings being Buy/Overweight equivalents. This high level of coverage and conviction provides a supportive backdrop for the stock.
- Strong Long-Term Technical Trend: The stock is up 134.6% over the past year, dramatically outperforming the S&P 500's 25.2% gain. Trading at 69% of its 52-week range ($36.36 to $120.74) suggests a consolidation within a powerful primary uptrend.
Bearish
- Deep and Persistent Losses: The company posted a Q4 2025 net loss of $128.5 million, with a net margin of -45.7%. Despite revenue growth, it remains deeply unprofitable, burning $220.8 million in free cash flow over the trailing twelve months.
- Extremely High Valuation Multiples: GH trades at a trailing Price-to-Sales ratio of 13.0 and an EV/Sales of 12.7. These are elevated multiples that price in near-perfect execution of future growth and a rapid path to profitability, leaving little room for error.
- High Volatility and Recent Weakness: The stock has a beta of 1.49, making it ~50% more volatile than the market. It is down 9.5% over the past three months and recently traded as low as $78.60, indicating significant price sensitivity and potential momentum loss.
- Valuation Compression from Historical Peaks: The current PS ratio of 13.0 is a massive compression from its historical peak of 195.9 in early 2021. While growth has materialized, this compression highlights the stock's vulnerability to multiple contraction if growth expectations falter.
GH Technical Analysis
The stock is in a pronounced long-term uptrend, evidenced by a staggering 134.60% gain over the past year, significantly outpacing the broader market's 25.19% return. Currently trading at $94.92, the price sits at approximately 69% of its 52-week range ($36.36 to $120.74), indicating it has retreated meaningfully from its highs but remains well above its lows, suggesting a consolidation phase within a larger bullish trend. Recent momentum, however, has diverged from this powerful annual trend, with the stock down 9.47% over the past three months and up 11.85% over the past month, signaling a period of volatility and potential base-building after the prior year's explosive move. The stock exhibits high volatility with a beta of 1.49, meaning it is roughly 50% more volatile than the S&P 500, which is critical for risk assessment and position sizing. Key technical levels are clearly defined, with major support at the 52-week low of $36.36 and immediate resistance at the 52-week high of $120.74; a decisive breakout above resistance would confirm a resumption of the primary uptrend, while a breakdown below the recent lows around $78.60 could signal a deeper correction is underway.
Beta
1.49
1.49x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$36-$121
Price range past year
Annual Return
+187.6%
Cumulative gain past year
| Period | GH Return | S&P 500 |
|---|---|---|
| 1m | +26.2% | +4.6% |
| 3m | +8.1% | +8.3% |
| 6m | +9.1% | +12.5% |
| 1y | +187.6% | +25.0% |
| ytd | +13.0% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GH Fundamental Analysis
Guardant Health is demonstrating explosive revenue growth, with Q4 2025 revenue reaching $281.3 million, representing a 39.4% year-over-year increase, and this acceleration is visible as quarterly revenue has climbed sequentially from $203.5 million in Q1 to the Q4 figure. Segment data reveals the Oncology business ($189.9 million) as the primary growth driver, complemented by contributions from Biopharma & Data ($54.0 million) and the emerging Screening segment ($35.1 million). Despite this robust top-line expansion, the company remains deeply unprofitable, posting a Q4 net loss of $128.5 million and a net margin of -45.7%, though the gross margin of 64.6% is healthy for the industry. The loss trajectory shows some improvement on a relative basis, as the net margin has improved from -68.2% in Q1 2024 to the current -45.7%, indicating operating leverage is beginning to materialize as revenue scales. The balance sheet shows a strong current ratio of 4.84, indicating good short-term liquidity, but the company is burning significant cash, with trailing twelve-month free cash flow at -$220.8 million, necessitating external financing to fund operations and growth; the negative debt-to-equity ratio of -16.94 is an accounting artifact from accumulated deficits and does not represent a traditional debt burden.
Quarterly Revenue
$281266000.0B
2025-12
Revenue YoY Growth
+0.39%
YoY Comparison
Gross Margin
+0.64%
Latest Quarter
Free Cash Flow
$-220777000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GH Overvalued?
Given the company's consistent net losses, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Guardant Health trades at a trailing PS ratio of 13.04 and an Enterprise Value-to-Sales (EV/Sales) of 12.67, which are elevated multiples that price in significant future growth expectations. Peer comparison data is not available in the provided dataset, preventing a direct sector premium/discount analysis; however, such high sales multiples typically command a substantial premium justified only by market leadership and hyper-growth prospects. Historically, the stock's own PS ratio has fluctuated dramatically, from a high of 195.9 in early 2021 down to the current 13.0, indicating the valuation has compressed massively as the company has grown into its revenue base, though it remains high relative to profitable med-tech peers, reflecting the ongoing speculative bet on its long-term market potential and path to profitability.
PE
-30.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -35x~-4x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-37.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on the company's path to profitability. Guardant Health is burning significant cash, with TTM free cash flow at -$220.8 million, necessitating future capital raises that could dilute shareholders. While the net margin improved to -45.7% in Q4 2025 from -68.2% in Q1 2024, losses remain deep, and the company's valuation (PS 13.0) is entirely dependent on continued hyper-growth to eventually justify the multiple. Any deceleration in the 39.4% revenue growth rate would severely pressure the stock, as the business model lacks a profitability cushion.
Market & Competitive Risks are pronounced due to the stock's premium valuation and high volatility. Trading at a PS ratio of 13.0, GH is vulnerable to valuation compression if growth stock multiples contract or if sector rotation away from unprofitable tech occurs. Its beta of 1.49 confirms high sensitivity to broader market swings. Competitively, the liquid biopsy space is attracting significant investment, and any technological or regulatory setback for Guardant's Shield or Reveal tests could cede market share. Recent news of novel cancer therapy approvals (e.g., Pfizer/Arvinas) underscores the rapid innovation in oncology, which could shift diagnostic priorities.
Worst-Case Scenario involves a combination of growth deceleration, sustained high cash burn, and a broader market downturn for growth stocks. This could trigger a vicious cycle of analyst downgrades, a failed equity offering, and a rapid re-rating toward its tangible asset value. The realistic downside can be quantified by the stock's 52-week low of $36.36, which represents a potential loss of approximately -62% from the current price of $94.92. The recent max drawdown of -33% also illustrates the stock's capacity for sharp corrections within its volatile trading pattern.
FAQ
The key risks are, in order of severity: 1) Valuation & Execution Risk: The high PS ratio of 13.0 means the stock is vulnerable to a sharp decline if revenue growth decelerates from 39.4% or losses widen. 2) Financial Risk: The company burns substantial cash (FCF TTM -$220.8M), requiring future financing that could dilute shareholders. 3) Operational Risk: The path to profitability is long, with a Q4 net margin of -45.7%. 4) Market Risk: The stock is 50% more volatile than the market (beta 1.49), making it sensitive to broader sell-offs and sector rotation away from unprofitable growth stocks.
The 12-month forecast is bifurcated, with a high degree of uncertainty. Our analysis outlines three scenarios: a Bull Case (25% probability) targeting $120-$140 if growth accelerates and margins improve sharply; a Base Case (55% probability) targeting $95-$115 if current growth and margin trends continue, meeting high expectations; and a Bear Case (20% probability) targeting $55-$75 if growth decelerates or losses expand. The Base Case is most likely, implying the stock may trade roughly sideways from current levels as the company executes well but struggles to exceed the lofty expectations baked into its price.
Based on traditional metrics, GH is significantly overvalued. It trades at a trailing Price-to-Sales ratio of 13.0 and an EV/Sales of 12.7, which are extreme multiples that imply the market expects many years of hyper-growth and eventual high profitability. While the company's revenue growth of 39.4% justifies a premium, the current valuation leaves no room for error. Compared to its own history, the multiple has compressed from a peak of 195.9, but it remains high. The valuation implies the market expects sustained >30% growth and a rapid transition to profitability.
GH is a high-risk, high-reward investment that is not a good buy for all investors. For aggressive growth investors with a long-term horizon and the stomach for volatility (beta 1.49), it offers exposure to a leading company in the transformative liquid biopsy space. The 39.4% YoY revenue growth is compelling. However, at a Price-to-Sales ratio of 13.0, the stock is expensive and priced for perfection, leaving significant downside risk (potentially -62% to its 52-week low) if growth stumbles. It may be a good buy on a meaningful pullback that offers a better risk/reward profile.
GH is unequivocally a long-term investment, unsuitable for short-term trading due to its high volatility (beta 1.49) and lack of near-term profitability catalysts. The investment thesis hinges on the multi-year scaling of its liquid biopsy platform, particularly the Shield screening test, to achieve profitability. Given the substantial cash burn and premium valuation, investors must be prepared to hold for 3-5 years minimum to allow the growth story to play out and for operating leverage to materially improve the bottom line. There is no dividend, and short-term price movements are likely to be driven by sentiment and quarterly execution against high expectations.